Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 122

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 122
---
 Open, along with the projected growth of the Traditional Chinese Medicine market, have contributed to this interest.

The Company has entered service agreements with firms in Hong Kong to accelerate product development in South-East Asia. These agreements aim to leverage local expertise and networks to facilitate market entry and potential out-licensing deals. The Company entered into an agreement with Dominant Treasure Health to expand its business development in China, Malaysia, and Singapore, aiming to penetrate the large and challenging Asian market.

| 67 |

During 2025, the Company initiated a transition toward two operating activities: (i) production and sale of premium nutritional supplements (marketed under the Nugevia® brand) and (ii) pharmaceutical operations focused on the development of drug candidates.

In March 2025, the Company announced that it had entered into a partnership with Aquanova to develop a series of nutritional products targeting longevity, aging and healthspan. The first three products, which will focus on the concept of longevity and healthspan, are available for sale and shipments are expected in the fourth quarter of 2025 through a DTC model. The Company will form a wholly-owned subsidiary to focus on the consumer market and will market its products through its website nugevia.com targeting the US market, along with social media marketing.. Once launched, the Company expects to generate product sales through (i) DTC e-commerce, including one-time purchases and auto-ship subscriptions, (ii) third-party online marketplaces, and (iii) wholesale/distributor channels. Internationally, the Company is focusing on partners who can market and accelerate sales, with an initial focus on the Asian region

On October 24, 2025, the Company entered into the SEPA and a related Registration Rights Agreement, each dated as of October 24, 2025, with Yorkville, pursuant to which the Company has the right to sell to Yorkville up to $20.0 million of its common stock, par value $0.0001 per share, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. Such shares of common stock registered under this prospectus include (i) up to 4,000,000 Conversion Shares that may be issued to Yorkville upon conversion by Yorkville of the Convertible Notes issued to Yorkville under the SEPA, (ii) 5,868,091 Advance Shares that may be issued to Yorkville in the form of one or more Advances under the SEPA in our